Pilot Study to Investigate the Role of Metabolic Imaging in Predicting Tumor Response and Outcome After Therapy for Pancreatic Cancer

Stanford University1 site in 1 country30 target enrollmentOctober 2006

Overview

To test the ability of new imaging techniques to monitor and predict response of pancreatic cancer to radiation and/or chemotherapy.

Registry

clinicaltrials.gov

Start Date

October 2006

End Date

December 2007

Last Updated

13 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Sponsor

Responsible Party

Principal Investigator

Albert Koong

Associate Professor of Radiation Oncology

Stanford University

•Adult patients (\>18) with histologically confirmed adenocarcinomas of the pancreas with a - treatment plan consisting of definitive or palliative radiation therapy and/or chemotherapy with or without surgery.
•Negative urine pregnancy test if a woman of child-bearing potential (WOCBP).
•WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study period.
•All patients will be evaluated in a uniform manner at the Stanford GI Combined Modality Tumor Board to determine eligibility.

•Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
•Any concurrent malignancy other than non-melanomaskin cancer, or carcinomainsitu of the cervix. Patients with a previous malignancy without evidence of disease for \>5 years will be allowed to enter the trial.
•WOCBP who is pregnant or breastfeeding.
•Inability to sign written consent.